Holen Sie sich die Stockscreener-App
26.49
1.07%
0.28
Handel nachbörslich:
26.49
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Geode Capital Management LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Wellington Management Group LLP Decreases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma's SWOT analysis: innovative pipeline drives stock potential - Investing.com
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Lifted by Barclays PLC - MarketBeat
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth By Investing.com - Investing.com South Africa
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth - Investing.com Australia
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest Position - MarketBeat
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP - BioCentury
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Yahoo Finance
Learn to Evaluate (BBIO) using the Charts - Stock Traders Daily
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Frazier Life Sciences Management L.P. Buys 127,853 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4%Should You Buy? - MarketBeat
Polar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Janus Henderson Group PLC Increases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Melqart Asset Management UK Ltd Grows Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HighVista Strategies LLC Acquires 24,482 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for - The Bakersfield Californian
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - Yahoo Finance
Erste Asset Management GmbH Invests $3.50 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma (BBIO) Stock Surges on FDA Approval of Lead Treatment - Nasdaq
BridgeBio Pharma (FRA:2CL) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
The week in pharma: action, reaction and insight – week to November 29 - The Pharma Letter
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More - Yahoo Finance
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - MSN
Intech Investment Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - MSN
HC Wainwright Has Optimistic Outlook of BBIO FY2024 Earnings - MarketBeat
Research Analysts Offer Predictions for BBIO FY2024 Earnings - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate - Morningstar
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings? - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - News & Insights
Health Care Up Amid Cyclical Bias -- Health Care Roundup - Marketscreener.com
Bridgebio, with FDA approval, faces Pfizer in ATTR - BioWorld Online
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race - FirstWord Pharma
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis - Yahoo Finance
Gold Down Over 3%; Rigetti Computing Shares Spike Higher - Benzinga
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - MedCity News
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment - Investing.com
BridgeBio stock retains Overweight; Piper Sandler highlights competitive pricing for Attruby - Investing.com
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):